Investors are always looking for the "right answers", especially during times of market turbulence like now. Will a recession begin? Is it better to buy or sell? The problem is that most of these questions don't have an answer - they require a solution. And both factually and psychologically, finding an answer and making a decision are different things. How do you learn to make decisions in the face of uncertainty? An economic model of the psyche can help, writes Konstantin Kunakh, psychologist, author of the <a href="https://www.litres.ru/book/konstantin-kunah/straday-s-tolkom-kniga-instrukciya-po-gramotnomu-ispolzov-71035111/">book</a> "Suffer with reason" and the<a href="https://t.me/usepain"> Telegram channel of</a> the same name.

How an economic model of the psyche can help investors 

This could create more problems for the oil market

Yemen's Houthis have entered the war on the side of Iran

The Estee Lauder Companies Inc.

Puig Brands SA

Ferrari N.V.

Rising oil prices, according to analysts' estimates, have raised the risk of recession in the US to 40% and could push inflation in the country to 5%. Automakers are recording supply disruptions and a slump in demand in the Middle East: Ferrari has started delivering supercars by airplanes, and the luxury sector has already lost $100 billion of capitalization. Against this background, OpenAI is preparing for an IPO, disclosing the risks of dependence on Microsoft, chip shortages and litigation, while Elon Musk's SpaceX may conduct the largest placement in history with a valuation of up to $1.75 trillion. The main events from March 23 to 27 - in our review.

Highlights of the week: US recession risks, SpaceX ambitions, war hits the luxury market

Micron Technology, Inc.

Micron shares collapsed more than 15% for the week and entered the bear market zone

One of last year's best stocks is now the cheapest in the S&amp;P 500. Is it worth buying?

Meta Platforms, Inc.

NVIDIA Corporation

Amazon.com, Inc.

Apple Inc.

Tesla, Inc.

Alphabet Inc.

Microsoft Corporation

The Magnificent Seven stocks cumulatively lost more than $850 billion in value over the week as the stock market sell-off hit the main beneficiaries of the AI rally particularly hard, Yahoo Finance <a href="https://finance.yahoo.com/news/magnificent-7-stocks-wipe-more-than-850-billion-in-value-as-stock-market-sell-off-hits-ai-winners-hard-213921360.html">writes</a>. Mag7 lost more than $330 billion on Friday alone, leading the <a href="https://oninvest.com/article/appetit-k-risku-ne-vyderzal-tumana-vojny-indeksy-ssa-na-minimume-s-avgusta">collapse</a>, the publication notes.

"The Magnificent Seven" lost $850 billion in value in a week. Who stayed in the black?

Now is definitely not the right time to take maximum risk, warns the banker who ran Goldman Sachs during the 2008 crisis 

'We haven't had the crisis of the century for a long time': ex-Goldman Sachs head on risks for investors

President Donald Trump is likely to further escalate the war with Iran, and if the current authorities of the Islamic republic retain control over the country, it could turn into "1970s-style stagflation" for the U.S., economist Nouriel Roubini <a href="https://www.cnbc.com/2026/03/27/nouriel-roubini-trump-iran-war-markets-oil-end-talks-peace.html">told</a> CNBC. He is known, in particular, for predicting the global financial crisis of 2008.

Economist who predicted the 2008 crisis does not believe in rapid de-escalation in Iran

Wall Street's fear index jumped above 31 points, an area of heightened uncertainty

"Risk appetite has failed to survive the fog of war": US indices at lowest since August

Data

Olaplex Holdings, Inc.

Shares of Olaplex, a small-cap premium hair care brand, surged more than 50% on Thursday. The company said it is set to be acquired at a premium by German conglomerate Henkel. The deal is a “welcome relief” for Olaplex investors, <a href="https://www.fool.com/coverage/stock-market-today/2026/03/26/stock-market-today-march-26-olaplex-shares-surge-after-henkel-agrees-to-usd1-4-billion-buyout/">reckons</a>&nbsp;Motley Fool contributor Josh Kohn-Lindquist. Since its IPO in 2021, the company’s shares have lost almost all their value, having fallen more than 90%, while its financial performance has largely stagnated.

'Welcome relief': Hair-care company Olaplex jumps after Henkel agrees to acquire it

Hims & Hers Health, Inc.

Novo Nordisk A/S

Eli Lilly and Company

LifeMD, Inc.

“The enemy of my enemy is my friend,” points out Ilya Zubkov, Freedom Broker senior equity analyst, describing the situation that has unfolded this year between Danish pharmaceutical giant Novo Nordisk and telehealth platform and online pharmacy operator Hims &amp; Hers Health. The “enemies” are Novo Nordisk and its U.S. rival Eli Lilly, which have been competing for leadership in the obesity drug market for several years. Their rivalry has spilled over beyond the pharmaceutical sector, now affecting companies like Hims &amp; Hers Health. Overall, the weight-loss drug market is beginning to shift. Which small caps should investors watch?

The obesity therapy market is changing. What smid-cap investors should know.

LANXESS Aktiengesellschaft

JPMorgan has upgraded shares of German chemicals group Lanxess AG by two notches and now <a href="https://www.bloomberg.com/news/articles/2026-03-25/lanxess-soars-as-jpmorgan-s-double-upgrade-provides-rare-boost">recommends</a>&nbsp;overweighting them. The company is set to gain a competitive advantage due to supply chain disruptions caused by the conflict in the Middle East, which should boost earnings, analysts said.

German chemical company Lanxess gets double upgraded by JPMorgan; shares soar

Terns Pharmaceuticals, Inc.

Merck & Co., Inc.

Pharmaceutical giant Merck, known outside of the U.S. and Canada as MSD, <a href="https://ir.ternspharma.com/news-releases/news-release-details/merck-acquire-terns-pharmaceuticals-inc-expanding-its-hematology">has agreed to acquire</a> mid-cap drug developer Terns Pharmaceuticals, which focuses on treatments for cancer and obesity. Following the news, shares of the mid cap <a href="https://finance.yahoo.com/quote/TERN/">rose</a>&nbsp;less than 6% on Wednesday. The price tag is low “considering the startlingly good data Terns put out for its chronic myeloid leukemia treatment,” William Blair analyst Andy Hsieh <a href="https://www.investors.com/news/technology/merck-terns-pharmaceuticals-takeover/?src=A00220">says</a>.

Merck to buy mid-cap biotech Terns, but William Blair thinks the price tag is low

Red Cat Holdings, Inc.

Ondas Inc.

Parrot S.A.

At the end of last year, at the NATO summit in The Hague, members set a <a href="https://www.nato.int/en/what-we-do/introduction-to-nato/defence-expenditures-and-natos-5-commitment#:~:text=At%2520the%25202025%2520NATO%2520Summit%2520in%2520The%2520Hague%252C%2520Allies%2520made%2520a%2520commitment%2520to%2520investing%25205%2525%2520of%2520Gross%2520Domestic%2520Product%2520(GDP)%2520annually%2520on%2520core%2520defence%2520requirements%2520and%2520defence%252D%2520and%2520security%252Drelated%2520spending%2520by%25202035">new benchmark</a>: defense spending at 5% of GDP by 2035. Of that, at least 3.5% is to be allocated to core military needs, and up to 1.5% to resilience, innovation, and the development of the defense industrial base. In the U.S., this has translated into consistent regulatory policy: following a <a href="https://www.whitehouse.gov/presidential-actions/2025/06/unleashing-american-drone-dominance/#:~:text=The%2520United%2520States%2520must%2520accelerate%2520the%2520safe%2520commercialization%2520of%2520drone%2520technologies%2520and%2520fully%2520integrate%2520UAS%2520into%2520the%2520National%2520Airspace%2520System.">White House executive order</a> in June 2025, the Pentagon in July <a href="https://media.defense.gov/2025/Jul/10/2003752117/-1/-1/1/UNLEASHING-U.S.-MILITARY-DRONE-DOMINANCE.PDF">moved</a> to accelerate procurement and deployment of small drones for the military. In January, the new National Defense Strategy <a href="https://media.defense.gov/2026/Jan/23/2003864773/-1/-1/0/2026-NATIONAL-DEFENSE-STRATEGY.PDF">established</a>&nbsp;countering drones as a priority. For the UAV industry, this marks a structural shift: demand is moving from one-off rush orders to formalized, long-term procurement programs. According to <a href="https://www.fortunebusinessinsights.com/drone-services-market-102682#:~:text=Global%20Drone%20Services%20Market%20Key%20Takeaways&amp;text=2025%20Market%20Size:%20USD%2032.08,:%2025.52%25%20from%202026%E2%80%932034">forecasts</a>, the global UAV market will grow from $42.4 billion in 2026 to $261.3 billion by 2034, implying a CAGR of 25.5%.

Oninvest military drone index outperforming small caps and broad market

Small Caps

Important news and analysis of global stock markets, plus crypto, bonds, and ETFs

Investment and Finance News